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Abstract 
Objectives: A retrospective examination was conducted to identify risk factors for in-hospital 
mortality of elderly patients (65 years or older) treated with the beta-lactam/beta-lactamase 
inhibitor combination antibiotic, ampicillin/sulbactam (ABPC/SBT).  
Methods: Clinical data from 96 patients who were hospitalized with infectious diseases and 
treated with ABPC/SBT (9 g/day or 12 g/day) were analyzed. Risk factors examined included 
demographic and clinical laboratory parameters. Parameter values prior to treatment and changes 
after treatment were compared between survivors and non-survivors. 
Results: The study patients had an average age of 81.9±8.4 years (±SD) and body mass index 
(BMI) of 19.9±4.2 kg/m2. They were characterized by anemia (low hemoglobin and hematocrit 
levels), inflammation (high leukocyte count, neutrophil count, C-reactive protein level, and body 
temperature), and hepatic and renal dysfunction (high aspartate aminotransferase, alanine 
aminotransferase and blood urea nitrogen levels). The BMI of non-survivors, 16.2±2.9 kg/m2, was 
lower than that of survivors, 20.4±4.1 kg/m2. In addition, the hematological parameters 
deteriorated more remarkably, inflammation markers were not altered (or the decrease was 
marginal), and hepatic function was not improved, in non-survivors. 
Conclusions: A lower BMI value is a risk factor for in-hospital mortality of elderly patients 
treated with ABPC/SBT. 
Key words: ampicillin/sulbactam, elderly patients, mortality, body mass index. 
Introduction 
Generally, elderly patients, usually defined as 
age 65 years or older, are often weak, undernourished, 
and hypokinetic, with delirium/dementia. They can 
also present a sudden change in motor function (e.g., 
balance impairment) when compared with younger 
patients. These characteristics are often described by 
the term “frail” [1]. Frailty has been recognized as an 
important factor influencing the prognosis of diseases 
after treatments [1]. However, there is no clinical 
indicator of frailty [1]. Elderly patients also show a 
higher prevalence of several diseases including 
diabetes, chronic renal or hepatic failure, congestive 
heart failure, malignancy, chronic pulmonary 








adversely affect treatment outcomes.  
Pneumonia is one of main causes of mortality in 
the elderly. In terms of severity of symptoms, the 
clinical presentation of pneumonia can be quite 
different from that observed in younger patients [1]. 
Microbiological patterns among elderly patients with 
community-acquired pneumonia (CAP) have been 
shown to be different from those of younger patients 
[2, 3]. These patterns in the elderly include higher 
rates of pneumococcal and influenza viral 
pneumonia, and lower presence of atypical pathogens 
[2, 3]. Elderly patients are also susceptible to 
multi-drug resistant pathogens, and they present 
more risk factors for aspiration pneumonia [1]. 
Epidemiological investigations suggest an increased 
tendency to infections, but this is not explained by 
suppression of immunological reactions [4]. 
Ampicillin/sulbactam (ABPC/SBT) is a 
beta-lactam/beta-lactamase inhibitor combination 
(dose ratio of 2:1) with broad spectrum of antibacterial 
activity against Gram-positive, Gram-negative and 
anaerobic bacteria [5]. It is used for treatment of lower 
respiratory tract infections and aspiration pneumonia, 
gynaecological/obstertrical infections, intra- 
abdominal infections, pediatric infections, diabetic 
foot infections and skin and soft tissue infections [5]. 
According to several international guidelines for the 
treatment of CAP published in 2007 to 2012 [6-8], 
ABPC/SBT (9 g/day at 3 g every 8 hr) is 
recommended for hospitalized patients with 
non-severe pneumonia [9]. The approved maximal 
daily dose of ABPC/SBT is 12 g (3 g every 6hr) in 
many countries. However, in Japan, it was recently 
shown that 12 g/day is well tolerated and provides 
excellent clinical and bacteriological responses [10]; 
this dose was approved in 2012. 
 In 2003, an international multicenter study was 
conducted in order to establish a practical severity 
assessment model for stratifying adults hospitalized 
with CAP into different management groups [11]. It 
was demonstrated that an age of 65 years or older was 
a risk factor for mortality [11]. In the present study, a 
retrospective examination was conducted to identify 
risk factors for in-hospital elderly patients, aged 65 
years or older, who were treated with ABPC/SBT. 
Changes after treatment were also compared between 
survivors and non-survivors to obtain additional 
information that could be used to more effectively 
manage elderly patients. 
Patient and Methods 
Eligibility 
All elderly patients (65 years or older) with 
infectious diseases were hospitalized and treated with 
9 g/day or 12 g/day of ABPC/SBT at Rakuwakai 
Otowa Hospital, Japan from December 2011 to July 
2012. Patients with the following conditions were 
excluded: 1) liver or renal dysfunctions (CTCAE 
[Common Terminology Criteria for Adverse Events] 
ver.4 grade 3 or higher), 2) undergoing cancer 
chemotherapy, 3) cardiopulmonary resuscitation, 4) 
ICU admission during hospitalization, or 5) operation 
during hospitalization. This retrospective study was 
approved by the ethics committee at Rakuwakai 
Otowa Hospital, Japan. 
Data analysis 
Patients were classified into two groups based 
on the mortality; i.e., survivors and non-survivors. 
Risk factors examined included age, gender, body 
weight, height, body mass index (BMI), and daily 
dose and number of doses of ABPC/SBT. 
Measurements of the following clinical laboratory 
parameters were made one day before, or on the day 
of, the start of treatment; erythrocyte count, 
hemoglobin, hematocrit, leukocyte count, neutrophil 
count, lymphocyte count, eosinophil count, basophil 
count, monocyte count, platelet count, aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), gamma-glutamyl transpeptidase (γ-GTP), total 
bilirubin (T-bil), alkaline phosphatase (ALP), lactate 
dehydrogenase (LDH), blood urea nitrogen (BUN), 
serum creatinine (Scr), C-reactive protein (CRP), and 
body temperature. These were also measured one day 
after the treatment. In cases where treatment ended 
within 3 days, the data were not included. If the 
patients died within 7 days after the last clinical 
laboratory test, the data were also excluded. 
Statistical analysis 
All values were reported as mean±standard 
deviations (SD). The unpaired Student`s 
t-test/Welch`s test or Mann-Whitney`s U test was 
used for two-groups comparisons of values. Fisher`s 
exact test was used for the analysis of contingency 
tables. P values of less than 0.05 were considered 
significant.  
Results 
Data from 96 patients were analyzed. 
Demographics, daily doses and number of doses of 
ABPC/SBT are summarized in Table 1. Clinical 
diagnoses included aspiration pneumonia (N=27), 
pneumonia (N=13), urinary tract infection (N=8), 
acute cholecystitis (N=6), acute cholangitis (N=5), 
choledocholithiasis cholangitis (N=5), acute 
pyelonephritis (N=4), complicated urinary tract 
infection (N=3), acute pneumonia (N=2) and others 
(N=23). Eighty-three patients (86.5 %) were survivors, 




whereas 13 were died after treatment. The causes of 
death included senility (N=3), aspiration pneumonia 
(N=2) and others (N=8). The average values for age, 
body weight and height were 81.9±8.4 years, 47.6±11.8 
kg, and 154.1±9.9 cm, respectively (Table 1). There 
were no statistical differences between survivors and 
non-survivors. However, the BMI of non-survivors, 
16.2±2.9 kg/m2, was significantly lower than that of 
survivors, 20.4±4.1 kg/m2.  
Table 2 shows values for 12 of the 20 clinical 
laboratory parameters measured prior to treatment of 
patients with ABPC/SBT. Patients were characterized 
by anemia (low hemoglobin and hematocrit levels), 
inflammation (high leukocyte count, neutrophil 
count, CRP level, and body temperature), and hepatic 
and renal dysfunction (high AST, ALT and BUN 
levels). No meaningful differences in clinical 
laboratory parameters were observed between 
survivors and non- survivors, except for neutrophil 
count and BUN. The neutrophil count for 
non-survivors was 7.2±4.8 x 103/μL, which was 
significantly lower than that for the survivors, 
10.0±5.6 x 103/μL. The BUN value for non-survivors 
was 31.3±28.3 mg/dL, which was significantly higher 
than that for the survivors, 20.5±13.4 mg/dL. There 
were no differences between survivors and 
non-survivors in the other 8 clinical laboratory 
parameters (data not shown). 
Values of clinical laboratory parameters 
measured after treatment with ABPC/SBT are 
summarized in Table 3. Non-survivors showed 
significantly lower values for erythrocyte count, 
hemoglobin, hematocrit and platelet count, and 
higher values for BUN and CRP than survivors. 
Changes after treatment with ABPC/SBT are shown 
in Table 4. The values for erythrocyte count, 
hemoglobin and hematocrit deteriorated more 
remarkably in non-survivors. Leukocyte and 
neutrophil counts were not changed, and levels of 
AST and ALT were not improved in non-survivors. 
 
 
Table 1. Characteristics of patients prior to treatment with 
ampicillin/sulbactam 
 Total Survivors Non-survivors 
Number of patients 96 83 13 
Age, years 81.9±8.4 81.6±8.5 84.2±7.8  
Gender, male/female 44/52 36/47 8/5 
Body weight, kg 47.6±11.8 48.4±11.7 40.5±9.8  
Height, cm  154.1±9.9 153.8±9.7 156.1±11.5 
Body mass index, kg/m2 19.9±4.2 20.4±4.1 16.2±2.9 * 
Dose, g/day 9.8±2.1 9.8±2.1 9.7±2.2 
Number of doses, /day 3.3±0.6 3.3±0.6 3.2±0.7 
Values are mean±standard deviations.  
* p < 0.05, compared with survivors. 
Table 2. Clinical laboratory parameters for patients prior to 
treatment with ampicillin/sulbactam. 
 Total Survivors Non-survivors 
Erythrocyte count, x 106/μl 4.1±0.7 4.1±0.7 3.8±0.8  
Hemoglobin, g/dL 12.4±2.2 12.5±2.2 11.4±2.5  
Hematocrit, % 37.1±6.4 37.5±6.1 34.8±7.8  
Leukocyte count, x 103/μl 11.0±5.8 11.4±5.8 8.6±5.2 
Neutrophil count, x 103/μl 9.6±5.6 10.0±5.6 7.2±4.8 * 
Platelet count, x 103/μl 201.3±82.4 202.9±77.1 191.1±114.4 
AST, U/L 78.6±204.6 86.6±219.1 27.2±10.2 
ALT, U/L 49.5±84.8 53.9±89.9 19.8±11.6 
BUN, mg/dL 22.0±16.4 20.5±13.4 31.3±28.3 * 
Serum creatinine, mg/dL 0.9±0.9 0.9±0.9 1.0±0.8 
CRP, mg/dL 7.7±7.5 7.8±7.8 7.3±6.2 
Body temperature, degrees 37.6±0.8 37.6±0.8 37.5±0.9 
Values are mean±standard deviations.  
* p < 0.05, compared with survivors. 
 
Table 3. Clinical laboratory parameters for patients after 
treatment with ampicillin/sulbactam. 
 Total Survivors Non-survivors 
Erythrocyte count, x 106/μl 3.7±0.6 3.8±0.6 3.1±0.6 * 
Hemoglobin, g/dL 11.1±1.9 11.4±1.7 9.3±1.7 * 
Hematocrit, % 33.9±5.5 34.7±5.0 28.3±5.3 * 
Leukocyte count, x 103/μl 6.3±3.2 6.0±2.0 8.5±6.8 
Neutrophil count, x 103/μl 4.5±3.2 4.1±1.9 7.2±6.8 
Platelet count, x 103/μl 237.3±88.2 246.0±84.0 181.8±97.2 * 
AST, U/L 31.0±21.3 30.2±20.7 35.6±25.3 
ALT, U/L 28.3±26.9 28.9±28.5 24.9±14.5 
BUN, mg/dL 13.1±15.4 11.2±7.2 24.8±36.8 * 
Scr, mg/dL 0.7±0.4 0.7±0.4 0.8±0.4 
CRP, mg/dL 2.8±3.6 2.5±3.7 4.3±2.4 * 
Body temperature, degrees 36.8±0.4 36.8±0.4 36.7±0.5 
Values are mean±standard deviations.  
* p < 0.05, compared with survivors. 
 
Table 4. Changes in clinical laboratory parameters after 
treatment with ampicillin/sulbactam. 
 Total Survivors Non-survivors 
Erythrocyte count, x 106/μl -0.4±0.4 -0.3±0.4 -0.7±0.4 * 
Hemoglobin, g/dL -1.3±1.3 -1.1±1.2 -2.1±1.2 * 
Hematocrit, % -3.2±4.0 -2.7±3.7 -6.5±4.0 * 
Leukocyte count, x 103/μl -4.7±6.3 -5.4±5.7 0.0±8.3 * 
Neutrophil count, x 103/μl -5.1±6.5 -5.9±5.7 0.0±8.3 * 
Platelet count, x 103/μl 36.0±76.1 43.0±70.6 -9.2±96.0 * 
AST, U/L -48.4±208.5 -57.8±223.7 8.5±19.9 
ALT, U/L -21.2±76.9 -25.4±81.5 6.8±11.4 * 
BUN, mg/dL -8.9±19.5 -9.3±12.7 -6.5±43.5 
Scr, mg/dL -0.1±0.6 -0.1±0.6 -0.2±0.7 
CRP, mg/dL -5.1±8.1 -5.4±8.4 -3.1±6.3 
Body temperature, degrees -0.7±1.0 -0.7±1.0 -0.8±0.9 
Values are mean±standard deviations.  




In this study, it was demonstrated that a lower 
BMI was a risk factor for in-hospital mortality of 
elderly patients treated with ABPC/SBT (Table 1). 
Recently, a large-scale meta-analysis on the 




association of BMI with all-cause mortality was 
published [12]. The sample size was over 2.88 million 
individuals and it included 270,000 deaths. Results 
showed that the mortality was lower in overweight 
(BMI 25-29.9 kg/m2), similar in grade 1 obesity (BMI 
30-34.9 kg/m2), and higher in grade 2/3 obesity (BMI 
35 kg/m2 or more), when compared with normal 
(BMI 18.5-24.9 kg/m2) [12]. Soon after this report, 
another study was published based on a sample size 
of over 70,000 elderly people [13]. This study 
demonstrated that underweight (BMI < 18.5 kg/m2) 
showed a higher mortality than normal BMI [13]. 
Taken together, these studies show that the 
association between BMI and mortality is U-shaped, 
with overweight or grade 1 obesity being at the 
minimum: this is the so-called ‘obesity paradox’ [14]. 
On the other hand, there are several reports 
showing a positive correlation between the BMI and 
the prevalence of hypertension and diabetes [15, 16]. 
The effect of triglycerides on coronary heart disease 
has also shown to be dependent on the BMI [17]. Bo et 
al. [18] suggested that the prognosis of 659 elderly 
patients admitted to medical intensive care units 
depended not only on the severity and age, but also 
on preexisting conditions. These conditions included 
loss of functional independence, severe and moderate 
cognitive impairment, and low BMI; higher mortality 
was found in the patients with lower BMI [18]. 
In our study, mean BMI values were 20.4 kg/m2 
and 16.2 kg/m2 for survivors and non-survivors, 
respectively. This results is consistent with the 
‘obesity paradox’ [14] and the report by Bo et al [18]. 
Other risk factors for mortality from our study 
included relatively low neutrophil count and high 
BUN (Table 2). Little information is available on 
mortality associated with neutrophil count, but renal 
impairment is a well-recognized risk factor for 
mortality. Further extensive examination with a large 
number of patients is needed to clarify the mortality 
predictability of clinical laboratory parameters. 
Treatment with ABPC/SBT had no effects on 
hematological parameters (erythrocyte count, and 
hemoglobin and hematocrit values) in survivors 
(Table 4). However, treatment did cause a decrease in 
these parameters in non-survivors (Table 4). Values 
for inflammation markers (leukocyte and neutrophil 
counts, and CRP value) were decreased for survivors, 
but not for non-survivors, values were either not 
altered or decrease was marginal (Table 4). Treatment 
with ABPC/SBT attenuated hepatic dysfunction in 
survivors, but no such attenuation was observed for 
non-survivors (Table 4). 
Adverse effects associated with ABPC/SBT 
include hematological abnormalities [5], and the 
mortality may be, at least in part, due to these effects. 
ABPC/SBT is primarily eliminated by renal excretion 
[5], and its pharmacokinetics depends on renal 
function [19-22]. In our study, values of Scr for all 
patients were within the normal range prior to 
treatment with ABPC/SBT (Table 2); therefore, we 
did not modify the dose. However, creatinine is 
formed in muscle tissues as a break-down product of 
creatine, and its formation is affected by age, gender, 
race, habits, diet, and chronic diseases [23]. As 
non-survivors showed a relatively low BMI, it is 
possible that the renal function was incorrectly 
estimated. As such, 9 g/day or 12 g/day ABPC/SBT 
had to be considered as a potential overdose for these 
patients. 
Craig and his co-workers [24] have conducted a 
series of investigations on the interrelationships 
between the pharmacokinetics and 
pharmacodynamics of a variety of antibiotics. They 
divided these antibiotics into 3 categories based on the 
pharmacokinetic parameters that determined efficacy. 
The efficacy of beta-lactam antibiotics, including 
ABPC/SBT, depends on the percentage of time that 
plasma concentrations exceed the minimum 
inhibitory concentration against the causative 
pathogen during the dosing interval. Thus, 12 g/day 
(3 g every 6 hr) of ABPC/SBT is assumed to be 
superior to 9 g/day (3g every 8 hr) in terms of 
efficacy. However, at present there is a lack of 
comparative data, especially for elderly patients, to 
make any definitive conclusion. Therefore, in this 
study, we divided patients into 2 groups based on the 
ABPC/SBT daily dose. No statistical differences 
between these 2 groups were observed in the clinical 
laboratory parameters or in mortality (data not 
shown). Our data suggested that 12 g/day of 
ABPC/SBT was as well tolerated as 9 g/day. This 
result is similar to findings from earlier study [10]. 
Our study has limitations. It addresses only 
all-cause mortality and not morbidity or 
cause-specific mortality. A variety of infectious 
diseases required the prescription of ABPC/SBT, but 
culture tests showed no micro-organisms after the 
treatment in all patients, suggesting that the mortality 
was not due to the lack of efficacy. High CRP values 
after the treatment with ABPC/SBT suggested chronic 
inflammation which was not related to infectious 
diseases. Especially for elderly patients, pre-existing 
conditions, including the frailty, affect the prognosis 
[1], but further analysis was limited by a small sample 
size.  
In conclusion, a lower BMI was a risk factor for 
in-hospital mortality of elderly patients treated with 
ABPC/SBT. In non-survivors, the hematological 
parameters deteriorated more remarkably, 
inflammation markers were not altered (or the 




decrease was marginal), and hepatic function was not 
improved. 
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